Beiersdorf posts results
This article was originally published in The Rose Sheet
Executive Summary
Sales for the company grew 7.3% in 2006 to $6.98 bil. (€1=$1.36), Chair of the Executive Board Thomas-B. Quaas states during April 26 annual general meeting in Hamburg, Germany. For the first quarter of 2007, sales for the consumer business segment "were up substantially" compared with the prior year, the exec adds, noting that the firm expects to report 7% to 8% growth for the division during its May 3 interim report. Beiersdorf aims to command 5.5% of the global market by 2010 by delivering superior brands, a process-driven global supply chain and growth in developing markets, Quaas says...
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.